Open AccessThe New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives
Author(s) -
Danilo Rocco,
Luigi Della Gravara,
Cesare Gridelli
Publication year - 2020
Publication title -
current clinical pharmacology
Language(s) - English
Resource type - Journals
eISSN - 2212-3938
pISSN - 1574-8847
DOI - 10.2174/1574884714666190809124555
Subject(s) - nivolumab , ipilimumab , medicine , immunotherapy , tolerability , lung cancer , oncology , cancer , intensive care medicine , adverse effect
In the recent years, immunotherapeutics and specifically immunecheckpoints inhibitors have marked a significant shift in the diagnostic and therapeutic algorithm of Non-Small Cell Lung Cancer (NSCLC), allowing us to use immunotherapeutics alone or combined with chemotherapy for a great subset of patients. However, new interesting approaches are being presently investigated, markedly immunotherapy combinations, that is, the use of two or more immunotherapeutics combined.